Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study.
about
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetesEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K StudySGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Cardiovascular safety of therapies for type 2 diabetes.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.Adverse Drug Events Associated with Low-Dose (10 mg) Versus High-Dose (25 mg) Empagliflozin in Patients Treated for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
P2860
Q26749281-BC5F4EDB-B877-436E-A51E-320627F78EA1Q30248634-A53E8F1E-7416-4117-BA2E-0C3628182E7AQ31117903-5FDF3FD4-E841-4D3F-B425-EBECEE9DC51DQ36327116-BDA7EDB4-4705-4AD7-93F5-AE55E5C0595BQ36756191-47913ADF-2377-452D-ABE3-D6D9E00C72D3Q38654762-4CB30F3A-30FE-4D47-B94E-7F04C7F32214Q38802437-690520EF-C408-4E2C-A281-929DA703E20AQ38824557-3D691F94-1994-4767-AD69-9C2CFE1FB4EBQ38908779-54EEB328-D1CC-46B4-A6FD-23C6D0B26CBCQ38960547-3B0CAE56-A4C2-4DB9-A2E3-918EC5EBCC94Q39000172-B6576BD7-ED6B-4071-8E7C-C224CC90648EQ40091881-9A0D9E0A-F06E-44AA-BFFE-5DBC4F6533E1Q47236288-A15D1E4C-EBDD-493C-9975-4D55D88D8E18Q52663367-D3286191-B278-4AA9-823C-F68436723C5C
P2860
Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Efficacy and safety of empagli ...... e-blind, parallel-group study.
@en
Efficacy and safety of empagli ...... e-blind, parallel-group study.
@nl
type
label
Efficacy and safety of empagli ...... e-blind, parallel-group study.
@en
Efficacy and safety of empagli ...... e-blind, parallel-group study.
@nl
prefLabel
Efficacy and safety of empagli ...... e-blind, parallel-group study.
@en
Efficacy and safety of empagli ...... e-blind, parallel-group study.
@nl
P2093
P2860
P1433
P1476
Efficacy and safety of empagli ...... e-blind, parallel-group study.
@en
P2093
Atsushi Taniguchi
Hans J Woerle
Henning Rattunde
Kazuki Koiwai
Masakazu Haneda
Takashi Kadowaki
Uli C Broedl
Yasuo Terauchi
P2860
P2888
P304
P356
10.1007/S12325-015-0198-0
P407
P577
2015-04-07T00:00:00Z